Učitavanje...
Safety and efficacy of targeted agents in metastatic kidney cancer patients with renal dysfunction
BACKGROUND: Multiple molecularly targeted agents (MTAs) have been approved for the management of metastatic renal cell carcinoma(mRCC). Sunitinib and M-TOR inhibitors (temsirolimus, everolimus) are primarily metabolized in the liver, while the metabolism of bevacizumab is unclear. There are limited...
Spremljeno u:
| Glavni autori: | , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2011
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3149855/ https://ncbi.nlm.nih.gov/pubmed/21799472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CAD.0b013e328346af0d |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|